Molecular basis of differential B-pentamer stability of Shiga toxins 1 and 2

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Conrady, Deborah G ^a   Flagler, Michael J ^b   Friedmann, David R ^c   Vander Wielen, Bradley D ^a   Kovall, Rhett A ^a   Weiss, Alison A ^a   Herr, Andrew B ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE; LEUCINE; VEROTOXIN 1; VEROTOXIN 2; ISOPROTEIN; RIBOSOME RNA;

ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; CRYSTAL STRUCTURE; MOLECULAR STABILITY; NONHUMAN; PHENOTYPE; POINT MUTATION; PROTEIN STABILITY; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; TOXIN ANALYSIS; ULTRACENTRIFUGATION; X RAY CRYSTALLOGRAPHY; AMINO ACID SEQUENCE; AREA UNDER THE CURVE; CONFORMATION; ESCHERICHIA COLI O157; GENETICS; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; STATISTICAL MODEL; TEMPERATURE;

ANIMALIA; ESCHERICHIA COLI;

AMINO ACID SEQUENCE; AREA UNDER CURVE; CIRCULAR DICHROISM; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI O157; MASS SPECTROMETRY; MODELS, STATISTICAL; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RNA, RIBOSOMAL; SHIGA TOXIN 1; SHIGA TOXIN 2; TEMPERATURE; ULTRACENTRIFUGATION;

EID: 78650828310     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015153     Document Type: Article

References (51)

1. Centers for Disease Control and Prevention. (2005) Disease listing, enterohemorrhagic E. coli.
2. Mead PS, Griffin PM (1998) Escherichia coli O157:H7. Lancet 352(9135): 1207-1212.
3. Boyce TG, Swerdlow DL, Griffin PM (1995) Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 333(6): 364-368.
4. Siegler RL (1995) The hemolytic uremic syndrome. Pediatr Clin North Am 42(6): 1505-1529.
5. Tilden J, Jr., Young W, McNamara AM, Custer C, Boesel B, et al. (1996) A new route of transmission for Escherichia coli: Infection from dry fermented salami. Am J Public Health 86(8): 1142-1145.
6. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342(26): 1930-1936.
7. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, et al. (1988) Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 171(1-2): 45-50.
8. Proulx F, Seidman EG, Karpman D (2001) Pathogenesis of Shiga toxinassociated hemolytic uremic syndrome. Pediatr Res 50(2): 163-171.
9. Slutsker L, Ries AA, Greene KD, Wells JG, Hutwagner L, et al. (1997) Escherichia coli O157:H7 diarrhea in the united states: Clinical and epidemiologic features. Ann Intern Med 126(7): 505-513.
10. Siegler RL, Obrig TG, Pysher TJ, Tesh VL, Denkers ND, et al. (2003) Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr Nephrol 18(2): 92-96.
11. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, et al. (1993) Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 61(8): 3392-3402.
12. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, et al. (1989) Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 160(6): 994-998.
13. Orth D, Grif K, Khan AB, Naim A, Dierich MP, et al. (2007) The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis 59(3): 235-242.
14. Kleanthous H, Smith HR, Scotland SM, Gross RJ, Rowe B, et al. (1990) Haemolytic uraemic syndromes in the British Isles, 1985-8: Association with verocytotoxin producing Escherichia coli. part 2: Microbiological aspects. Arch Dis Child 65(7): 722-727.
15. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, et al. (1999) Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 37(3): 497-503.
16. Merritt EA, Hol WG (1995) AB5 toxins. Curr Opin Struct Biol 5(2): 165-171.
17. Donohue-Rolfe A, Keusch GT, Edson C, Thorley-Lawson D, Jacewicz M (1984) Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies. J Exp Med 160(6): 1767-1781.
18. Fraser ME, Chernaia MM, Kozlov YV, James MN (1994) Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A ° resolution. Nat Struct Biol 1(1): 59-64.
19. Fraser ME, Fujinaga M, Cherney MM, Melton-Celsa AR, Twiddy EM, et al. (2004) Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem 279(26): 27511-27517.
20. Jacewicz M, Clausen H, Nudelman E, Donohue-Rolfe A, Keusch GT (1986) Pathogenesis of Shigella diarrhea. XI. isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med 163(6): 1391-1404.
21. Head SC, Karmali MA, Lingwood CA (1991) Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. evidence for B subunit modulation of a subunit function. J Biol Chem 266(6): 3617-3621.
22. Lingwood CA (1996) Role of verotoxin receptors in pathogenesis. Trends Microbiol 4(4): 147-153.
23. Marcato P, Vander Helm K, Mulvey GL, Armstrong GD (2003) Serum amyloid P component binding to Shiga toxin 2 requires both a subunit and B pentamer. Infect Immun 71(10): 6075-6078.
24. Weinstein DL, Jackson MP, Perera LP, Holmes RK, O'Brien AD (1989) In vivo formation of hybrid toxins comprising Shiga toxin and the Shiga-like toxins and role of the B subunit in localization and cytotoxic activity. Infect Immun 57(12): 3743-3750.
25. Nelson S (1994) In: Karmali MA, Golgio AG, eds. Recent advances in verocytotoxin-producing Escherichia coli infections. Elsevier Science. pp 245-248.
26. Kitova EN, Daneshfar R, Marcato P, Mulvey GL, Armstrong G, et al. (2005) Stability of the homopentameric B subunits of Shiga toxins 1 and 2 in solution and the gas phase as revealed by nanoelectrospray fourier transform ion cyclotron resonance mass spectrometry. J Am Soc Mass Spectrom 16(12): 1957-1968.
27. Kitova EN, Mulvey GL, Dingle T, Sinelnikov I, Wee S, et al. (2009) Assembly and stability of the Shiga toxins investigated by electrospray ionization mass spectrometry. Biochemistry 48(23): 5365-5374.
28. Pina DG, Gomez J, Villar E, Johannes L, Shnyrov VL (2003) Thermodynamic analysis of the structural stability of the Shiga toxin B-subunit. Biochemistry 42(31): 9498-9506.
29. Tomoda H, Arai M, Koyama N, Matsui H, Omura S, et al. (2002) Purification of Shiga-like toxin 1 by pigeon egg white glycoproteins immobilized on sepharose gels. Anal Biochem 311(1): 50-56.
30. Miyake M, Utsuno E, Noda M (2000) Binding of avian ovomucoid to Shiga-like toxin type 1 and its utilization for receptor analog affinity chromatography. Anal Biochem 281(2): 202-208.
31. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, et al. (2005) Protein identification and analysis tools on the ExPASy server. In: Walker JM, ed. The Proteomics Protocols Handbook.: Humana Press. pp 571-607.
32. Schuck P (2000) Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys J 78(3): 1606-1619.
33. Conrady DG, Brescia CC, Horii K, Weiss AA, Hassett DJ, et al. (2008) A zincdependent adhesion module is responsible for intercellular adhesion in staphylococcal biofilms. Proc Natl Acad Sci U S A 105(49): 19456-19461.
34. Andrade MA, Chacon P, Merelo JJ, Moran F (1993) Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Protein Eng 6(4): 383-390.
35. Whitmore L, Wallace BA (2008) Protein secondary structure analyses from circular dichroism spectroscopy: Methods and reference databases. Biopolymers 89(5): 392-400.
36. Greenfield NJ (2006) Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions. Nat Protoc 1(6): 2527-2535.
37. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Method Enzymol 276: 307-326.
38. Storoni LC, McCoy AJ, Read RJ (2004) Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr 60(Pt 3): 432-438.
39. Winn MD, Isupov MN, Murshudov GN (2001) Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr 57(Pt 1): 122-133.
40. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1): 2126-2132.
41. Laskowski RA, Macarthur MW, Moss DS, Thornton JM (1993) Procheck - a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography 26: 283-291.
42. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, et al. (2007) MolProbity: All-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35 (Web Server issue): W375-83.
43. Correia JJ, Alday PH, Sherwood P, Stafford WF (2009) Effect of kinetics on sedimentation velocity profiles and the role of intermediates. Methods Enzymol 467: 135-161.
44. Gilbert GA (1959) Sedimentation and electrophoresis of interacting substances I. Idealized boundary shape for a single substance aggregating reversibly. Proceedings of the Royal Society of London. Series A. Mathematical and Physical Sciences 250: 377-388.
45. Fersht A (1999) Structure and mechanism in protein science: A guide to enzyme catalysis and protein folding. New York: W.H. Freeman. 631 p.
46. Pina DG, Stechmann B, Shnyrov VL, Cabanie L, Haicheur N, et al. (2008) Correlation between Shiga toxin B-subunit stability and antigen crosspresentation: A mutational analysis. FEBS Lett 582(2): 185-189.
47. Pina DG, Gomez J, England P, Craescu CT, Johannes L, et al. (2006) Characterization of the non-native trifluoroethanol-induced intermediate conformational state of the Shiga toxin B-subunit. Biochimie 88(9): 1199-1207.
48. Kulkarni AA, Fuller C, Korman H, Weiss AA, Iyer SS (2010) Glycan encapsulated gold nanoparticles selectively inhibit Shiga toxins 1 and 2. Bioconjug Chem 21(8): 1486-1493.
49. Lee JE, Reed J, Shields MS, Spiegel KM, Farrell LD, et al. (2007) Phylogenetic analysis of Shiga toxin 1 and Shiga toxin 2 genes associated with disease outbreaks. BMC Microbiol 7: 109.
50. Ling H, Pannu NS, Boodhoo A, Armstrong GD, Clark CG, et al. (2000) A mutant Shiga-like toxin IIe bound to its receptor gb(3): Structure of a group II Shiga-like toxin with altered binding specificity. Structure 8(3): 253-264.
51. Asakura H, Makino S, Kobori H, Watarai M, Shirahata T, et al. (2001) Phylogenetic diversity and similarity of active sites of Shiga toxin (stx) in Shiga toxin-producing Escherichia coli (STEC) isolates from humans and animals. Epidemiol Infect 127(1): 27-36.